The paradoxical patterns of expression of indoleamine 2,3-dioxygenase in colon cancer

Journal of Translational Medicine

Volumn 7, Issue , 2009, Pages

  Gao, Yan Fang ^a,b,c   Peng, Rui Qing ^a,b   Li, Jiang ^a,b   Ding, Ya ^a,b   Zhang, Xing ^a,b   Wu, Xiao Jun ^a,b   Pan, Zhi Zhong ^a,b   Wan, De Sen ^a,b   Zeng, Yi Xin ^a,b   Zhang, Shi ^a,b  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b SUN YAT SEN UNIVERSITY   (China)

^c WEIFANG PEOPLE'S HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

INDOLEAMINE 2,3 DIOXYGENASE; PROTEIN BIN1; REGULATOR PROTEIN; UNCLASSIFIED DRUG; BIN1 PROTEIN, HUMAN; NUCLEAR PROTEIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TUMOR SUPPRESSOR PROTEIN;

ADULT; ARTICLE; CANCER CELL; CANCER STAGING; CANCER SURVIVAL; CELL DENSITY; CELL FUNCTION; COLON CANCER; CONTROLLED STUDY; CYTOPLASM; DOWN REGULATION; EPITHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SURVIVAL RATE; COLON TUMOR; CYTOLOGY; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; LYMPH NODE; METABOLISM; MIDDLE AGED; PATHOLOGY;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; COLONIC NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NUCLEAR PROTEINS; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEINS;

EID: 70049096598     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-7-71     Document Type: Article

References (56)

1. Munn DH Mellor AL Indoleamine 2,3-dioxygenase and tumor-induced tolerance J Clin Invest 2007, 117(5):1147-1154 10.1172/JCI31178 1857253 17476344
2. Takikawa O Biochemical and medical aspects of the indoleamine 2,3-dioxy-genase-initiated L-tryptophan metabolism Biochem Biophys Res Commun 2005, 338(1):12-19 10.1016/j.bbrc.2005.09.032 16176799
3. King NJ Thomas SR Molecules in focus: Indoleamine 2,3-dioxygenase Int J Biochem Cell Biol 2007, 39(12):2167-2172 10.1016/j.biocel.2007.01.004 17320464
4. Munn DH Indoleamine 2,3-dioxygenase, tumor-induced tolerance and counter-regulation Curr Opin Immunol 2006, 18(2):220-225 10.1016/ j.coi.2006.01.002 16460921
5. Munn DH Zhou M Attwood JT Bondarev I Conway SJ Marshall B Brown C Mellor AL Prevention of allogeneic fetal rejection by tryptophancatabolism Science 1998, 281(5380):1191-1193 10.1126/science.281.5380.1191 9712583
6. Mellor AL Munn DH IDO expression by dendritic cells: Tolerance and tryptophan catabolism Nat Rev Immunol 2004, 4(10):762-774 10.1038/ nri1457 15459668
7. Alexander AM Crawford M Bertera S Rudert WA Takikawa O Robbins PD Trucco M Indoleamine 2,3-dioxygenase expression in transplanted NOD Islets prolongs graft survival after adoptive transfer of diabetogenic splenocytes Diabetes 2002, 51(2):356-365 10.2337/diabetes.51.2.356 11812742
8. Jalili RB Rayat GR Rajotte RV Ghahary A Suppression of islet allogeneic immune response by indoleamine 2,3 dioxygenase-expressing fibroblasts J Cell Physiol 2007, 213(1):137-143 10.1002/jcp.21100 17477384
9. Hayashi T Beck L Rossetto C Gong X Takikawa O Takabayashi K Broide DH Carson DA Raz E Inhibition of experimental asthma by indoleamine 2,3-dioxygenase J Clin Invest 2004, 114(2):270-279 449749 15254594
10. Uyttenhove C Pilotte L Théate I Stroobant V Colau D Parmentier N Boon T Eynde Van den BJ Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase Nat Med 2003, 9(10):1269-1274 10.1038/nm934 14502282
11. Zheng X Koropatnick J Li M Zhang X Ling F Ren X Hao X Sun H Vladau C Franek JA Feng B Urquhart BL Zhong R Freeman DJ Garcia B Min WP Reinstalling antitumor immunity by inhibiting tumor-derived immuno-suppressive molecule IDO through RNA interference J Immunol 2006, 177(8):5639-5646 17015752
12. Ino K Yoshida N Kajiyama H Shibata K Yamamoto E Kidokoro K Takahashi N Terauchi M Nawa A Nomura S Nagasaka T Takikawa O Kikkawa F Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial cancer Br J Cancer 2006, 95(11):1555-1561 10.1038/sj.bjc.6603477 17117179
13. Brandacher G Perathoner A Ladurner R Schneeberger S Obrist P Winkler C Werner ER Werner-Felmayer G Weiss HG Göbel G Margreiter R Königsrainer A Fuchs D Amberger A Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: Effect on tumor-infiltrating T cells Clin Cancer Res 2006, 12(4):1144-1151 10.1158/ 1078-0432.CCR-05-1966 16489067
14. Chen PW Mellon JK Mayhew E Wang S He YG Hogan N Niederkorn JY Uveal melanoma expression of indoleamine 2,3-deoxygenase: Establishment of an immune privileged environment by tryptophan depletion Exp Eye Res 2007, 85(5):617-625 10.1016/j.exer.2007.07.014 2695208 17870068
15. Sedlmayr P Semlitsch M Gebru G Karpf E Reich O Tang T Wintersteiger R Takikawa O Dohr G Expression of indoleamine 2,3-dioxygenase in carcinoma of human endometrium and uterine cervix Adv Exp Med Biol 2003, 527:91-95 15206720
16. Karanikas V Zamanakou M Kerenidi T Dahabreh J Hevas A Nakou M Gourgoulianis KI Germenis AE Indoleamine 2,3-dioxygenase (IDO) expression in lung cancer Cancer Biol Ther 2007, 6(8):1258-262 17700060
17. Pan K Wang H Chen MS Zhang HK Weng DS Zhou J Huang W Li JJ Song HF Xia JC Expression and prognosis role of indoleamine 2,3-dioxygenase in hepatocellular carcinoma J Cancer Res Clin Oncol 2008, 134(11):1247-1253 10.1007/s00432-008-0395-1 18438685
18. Riesenberg R Weiler C Spring O Eder M Buchner A Popp T Castro M Kammerer R Takikawa O Hatz RA Stief CG Hofstetter A Zimmermann W Expression of indoleamine 2,3-dioxygenase in tumor endothelial cells correlates with long-term survival of patients with renal cell carcinoma Clin Cancer Res 2007, 13(23):6993-7002 10.1158/1078-0432.CCR-07-0942 18056175
19. Takao M Okamoto A Nikaido T Urashima M Takakura S Saito M Saito M Okamoto S Takikawa O Sasaki H Yasuda M Ochiai K Tanaka T Increased synthesis of indoleamine-2,3-dioxygenase protein is positively associated with impaired survival in patients with serous-type, but not with other types of, ovarian cancer Oncol Rep 2007, 17(6):1333-1339 17487387
20. Travers MT Gow IF Barber MC Thomson J Shennan DB Indoleamine 2,3-dioxygenase activity and L-tryptophan transport in human breast cancer cells Biochim Biophys Acta 2004, 1661(1):106-12 10.1016/ j.bbamem.2003.12.004 14967480
21. Ino K Yamamoto E Shibata K Kajiyama H Yoshida N Terauchi M Nawa A Nagasaka T Takikawa O Kikkawa F Inverse correlation between tumoral indoleamine 2,3-dioxygenase expression and tumor-infiltrating lymphocytes in endometrial cancer: Its association with disease progression and survival Clin Cancer Res 2008, 14(8):2310-2317 10.1158/ 1078-0432.CCR-07-4144 18413819
22. Munn DH Mellor AL The tumor-draining lymph node as an immune-privileged site Immunol Rev 2006, 213:146-158 10.1111/j.1600-065X.2006.00444.x 16972902
23. Terness P Chuang JJ Opelz G The immunoregulatory role of IDO-producing human dendritic cells revisited Trends Immunol 2006, 27:68-73 10.1016/ j.it.2005.12.006 16406698
24. Löb S Königsrainer A Is IDO a key enzyme bridging the gap between tumor escape and tolerance induction? Langenbecks Arch Surg 2008, 393(6):995-1003 10.1007/s00423-007-0245-7 18064486
25. Negin B Panka D Wang W Siddiqui M Tawa N Mullen J Tahan S Mandato L Polivy A Mier J Atkins M Effect of melanoma on immune function in the regional lymph node basin Clin Cancer Res 2008, 14(3):654-659 10.1158/ 1078-0432.CCR-07-1577 18245524
26. Yen MC Lin CC Chen YL Huang SS Yang HJ Chang CP Lei HY Lai MD A novel cancer therapy by skin delivery of indoleamine 2,3-dioxygenase siRNA Clin Cancer Res 2009, 15:641-649 10.1158/1078-0432.CCR-08-1988 19147770
27. Ou X Cai S Liu P Zeng J He Y Wu X Du J Enhancement of dendritic cell-tumor fusion vaccine potency by indoleamine-pyrrole 2,3-dioxygenase inhibitor, 1-MT J Cancer Res Clin Oncol 2008, 134:525-533 10.1007/ s00432-007-0315-9 17909857
28. Miyazaki T Moritake K Yamada K Hara N Osago H Shibata T Akiyama Y Tsuchiya M Indoleamine 2,3-dioxygenase as a new target for malignant glioma therapy J Neurosurg 2009 19199463
29. Hou DY Muller AJ Sharma MD DuHadaway J Banerjee T Johnson M Mellor AL Prendergast GC Munn DH Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses Cancer Res 2007, 67(2):792-801 10.1158/ 0008-5472.CAN-06-2925 17234791
30. MacKenzie CR Heseler K Müller A Däubener W Role of indoleamine 2,3-dioxygenase in antimicrobial defence and immuno-regulation: tryptophan depletion versus production of toxic kynurenines Curr Drug Metab 2007, 8(3):237-244 10.2174/138920007780362518 17430112
31. Burke F Knowles RG East N Balkwill FR The role of indoleamine 2,3-dioxygenase in the anti-tumour activity of human interferon-gamma in vivo Int J Cancer 1995, 60(1):115-122 10.1002/ijc.2910600117 7814143
32. Gasparri AM Jachetti E Colombo B Sacchi A Curnis F Rizzardi GP Traversari C Bellone M Corti A Critical role of indoleamine 2,3-dioxygenase in tumor resistance to repeated treatments with targeted IFNgamma Mol Cancer Ther 2008, 7(12):3859-3866 10.1158/ 1535-7163.MCT-08-0538 19074858
33. Melichar B Hu W Patenia R Melicharová K Gallardo ST Freedman R rIFN-gamma-mediated growth suppression of platinum-sensitive and -resistant ovarian tumor cell lines not dependent upon arginase inhibition J Transl Med 2003, 1(1):5 10.1186/1479-5876-1-5 222988 14572312
34. Karanikas V Speletas M Zamanakou M Kalala F Loules G Kerenidi T Barda AK Gourgoulianis KI Germenis AE Foxp3 expression in human cancer cells J Transl Med 2008, 6:19 10.1186/1479-5876-6-19 2386447 18430198
35. Slingluff CL Jr Speiser DE Progress and controversies in developing cancer vaccines J Transl Med 2005, 3(1):18 10.1186/1479-5876-3-18 1142519 15862126
36. Nagorsen D Voigt S Berg E Stein H Thiel E Loddenkemper C Tumor-infiltrating macrophages and dendritic cells in human colorectal cancer: Relation to local regulatory T cells, systemic T-cell response against tumor-associated antigens and survival J Transl Med 2007, 5:62 10.1186/1479-5876-5-62 2212626 18047662
37. Gastl G Spizzo G Obrist P Dünser M Mikuz G Ep-CAM overexpression in breast cancer as a predictor of survival Lancet 2000, 356(9246):1981-1982 10.1016/S0140-6736(00)03312-2 11130529
38. Sharma MD Baban B Chandler P Hou DY Singh N Yagita H Azuma M Blazar BR Mellor AL Munn DH Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase J Clin Invest 2007, 117(9):2570-2582 10.1172/JCI31911 1940240 17710230
39. von Bergwelt-Baildon MS Popov A Saric T Chemnitz J Classen S Stoffel MS Fiore F Roth U Beyer M Debey S Wickenhauser C Hanisch FG Schultze JL CD25 and indoleamine 2,3-dioxygenase are up-regulated by prostaglandin E2 and expressed by tumor-associated dendritic cells in vivo: Additional mechanisms of T-cell inhibition Blood 2006, 108(1):228-237 10.1182/ blood-2005-08-3507 16522817
40. Munn DH Sharma MD Hou D Baban B Lee JR Antonia SJ Messina JL Chandler P Koni PA Mellor AL Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes J Clin Invest 2004, 114(2):280-290 449750 15254595
41. Kahler DJ Mellor AL T cell regulatory plasmacytoid dendritic cells expressing indoleamine 2,3 dioxygenase Handb Exp Pharmacol 2009, 188-165 196 full_text 19031026
42. Liu JY Zhang XS Ding Y Peng RQ Cheng X Zhang NH Xia JC Zeng YX The changes of CD4+CD25+/CD4+ proportion in spleen of tumor-bearing BALB/c mice J Transl Med 2005, 3(1):5 10.1186/1479-5876-3-5 549051 15679891
43. Gajewski TF Meng Y Blank C Brown I Kacha A Kline J Harlin H Immune resistance orchestrated by the tumor microenvironment Immunol Rev 2006, 213:131-145 10.1111/j.1600-065X.2006.00442.x 16972901
44. Zou W Regulatory T cells, tumour immunity and immunotherapy Nat Rev Immunol 2006, 6(4):295-307 10.1038/nri1806 16557261
45. Watanabe S Deguchi K Zheng R Tamai H Wang LX Cohen PA Shu S Tumor-induced CD11b+Gr-1+ myeloid cells suppress T cell sensitization in tumor-draining lymph nodes J Immunol 2008, 181(5);3291-300 18714001
46. Polak ME Borthwick NJ Gabriel FG Johnson P Higgins B Hurren J McCormick D Jager MJ Cree IA Mechanisms of local immuno-suppression in cutaneous melanoma Br J Cancer 2007, 96(12):1879-1887 10.1038/sj.bjc.6603763 17565341
47. Ichim TE Zhong Z Kaushal S Zheng X Ren X Hao X Joyce JA Hanley HH Riordan NH Koropatnick J Bogin V Minev BR Min WP Tullis RH Exosomes as a tumor immune escape mechanism: Possible therapeutic implications J Transl Med 2008, 6:37 10.1186/1479-5876-6-37 2504474 18644158
48. Huber V Filipazzi P Iero M Fais S Rivoltini L More insights into the immunosuppressive potential of tumor exosomes J Transl Med 2008, 6:63 10.1186/1479-5876-6-63 2590595 18973649
49. Fallarino F Gizzi S Mosci P Grohmann U Puccetti P Tryptophan catabolism in IDO+ plasmacytoid dendritic cells Curr Drug Metab 2007, 8(3):209-216 10.2174/138920007780362581 17430109
50. Muller AJ DuHadaway JB Donover PS Sutanto-Ward E Prendergast GC Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy Nat Med 2005, 11(3):312 -319 10.1038/nm1196 15711557
51. Prendergast GC Immune escape as a fundamental trait of cancer: Focus on IDO Oncogene 2008, 27(28):3889-3900 10.1038/onc.2008.35 18317452
52. Witkiewicz A Williams TK Cozzitorto J Durkan B Showalter SL Yeo CJ Brody JR Expression of indoleamine 2,3-dioxygenase in metastatic pancreatic ductal adenocarcinoma recruits regulatory T cells to avoid immune detection J Am Coll Surg 2008, 206(5):849-54 10.1016/ j.jamcollsurg.2007.12.014 18471709
53. Zamanakou M Germenis AE Karanikas V Tumor immune escape mediated by indoleamine 2,3-dioxygenase Immunol Lett 2007, 111(2):69-75 10.1016/ j.imlet.2007.06.001 17644189
54. Yoshida N Ino K Ishida Y Kajiyama H Yamamoto E Shibata K Terauchi M Nawa A Akimoto H Takikawa O Isobe K Kikkawa F Overexpression of indoleamine 2,3-dioxygenase in human endometrial carcinoma cells induces rapid tumor growth in a mouse xenograft model Clin Cancer Res 2008, 14(22):7251-7259 10.1158/1078-0432.CCR-08-0991 19010841
55. Battaglia A Buzzonetti A Baranello C Ferrandina G Martinelli E Fanfani F Scambia G Fattorossi A Metastatic tumour cells favour the generation of a tolerogenic milieu in tumour draining lymph node in patients with early cervical cancer Cancer Immunol Immunother 2009, 58(9):1363-73 10.1007/s00262-008-0646-7 19172271
56. Löb S Königsrainer A Rammensee HG Opelz G Terness P Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: Can we see the wood for the trees? Nat Rev Cancer 2009, 9(6):445-52 10.1038/nrc2639 19461669